$UnitedHealth(UNH)$  buy when no people want, sell when all people want 

$UnitedHealth(UNH)$  UnitedHealth Group (UNH), once a quiet rock in your portfolio, just hit a speed bump. After a powerful rebound from its early-year lows, the rally screeched to a halt following a well-timed analyst downgrade. Now, with UNH hovering near the critical $300 level, investors are left wondering: Is this a healthy pullback — or a warning sign to get out before the chart codes blue? What’s Going On? UNH’s rally was impressive, bouncing back over 20% from YTD lows as optimism returned to the healthcare sector. But a recent downgrade citing margin pressures, Medicare challenges, and potential regulatory headwinds hit the brakes. Investors fear the glory days of smooth premium growth and defensive stability

$UnitedHealth(UNH)$  vbhh vgbgfgfg ggfd 

$UnitedHealth(UNH)$    @Shyon @Aqa @SPACE ROCKET @TigerGPT @nomadic_m @Barcode @LMSunshine @koolgal @rL @GoodLife99

After a brutal selloff, UnitedHealth shares staged a three-day rally, climbing to $321.58. The bounce followed CEO Stephen Hemsley's $25 million stock purchase—86,700 shares at $288.57 each—disclosed in a Friday SEC filing.Is this a sign the bottom is in?Would you buy, hold, or sell at $300?Could UNH be on its way back to $400?🎁Special Notes: Whoever showed up on the” What the Tigers Say” column will receive 100 Tiger Coins and an exclusive interview invitation to honor your contribution.Click titles to read the full analysis:1. @yourcelesttyy: Key Points:UNH’s turmoil isn’t just a company story—it’s a bellwether for the healthcare sector:Insider Confidence: Hemsley’s purchase, combined with CFO and other executive buying, signals that

UnitedHealth Group ( $UnitedHealth(UNH)$ ) has been on a wild ride, plummeting over 50% year-to-date to a low of $288.57 before staging a three-day rally to $321.66, sparked by new CEO Stephen Hemsley’s bold $25 million purchase of 86,700 shares. This insider move, coupled with other executive buying, has investors buzzing: is this a generational buying opportunity, or a fleeting bounce before more pain? With the stock trading at a discount and questions lingering about a return to $400, let’s unpack the catalysts, risks, and whether you should buy, sell, or hold at $300. 🔍 What’s Happening? UNH’s stock has been battered by a perfect storm of challenges: Earnings Blowup: In Q1 2025, UNH reported a minor earnings miss and withdrew its full-year guid

$UnitedHealth(UNH)$  If can survive this storm, the island will be full of fruits.. or Otherwise, sharks will be waiting below.

For those who took a position. Key is to exit with profits or break even.  $UnitedHealth(UNH)$  

$UnitedHealth(UNH)$  The Department of Justice (DOJ) is investigating UnitedHealth Group (UNH) for potential Medicare fraud. While specifics remain undisclosed, reports indicate the investigation centers on the company's Medicare Advantage business practices. This is a criminal investigation, separate from a previously reported antitrust investigation concerning the relationship between UNH's insurance division and its Optum health services segment. The antitrust investigation also includes scrutiny of UNH's doctor-group acquisitions and Medicare billing. The ongoing investigations contribute to the uncertainty surrounding UNH's stock performance . The precise timeline of the DOJ's criminal investigation into UnitedHe

$UnitedHealth(UNH)$  When a company insider opens their wallet, investors pay attention. But when the CEO of UnitedHealth Group (UNH) drops a whopping $25 million to buy shares on the open market, that’s more than just confidence — it’s a bold statement. After a brutal YTD performance, with the stock shedding nearly 50% from its highs, UNH’s sharp correction has raised eyebrows across Wall Street. Regulatory pressures, margin concerns, and Medicare-related headwinds all weighed heavily on sentiment. But now, with this insider vote of confidence, the tide may be turning. What Does a $25M Insider Buy Signal? Valuation Floor? Insiders only buy for one reason: they think the stock is undervalued. UNH's drop brought its P/

$UnitedHealth(UNH)$   I recently came across some intriguing news about UnitedHealth that caught my attention as an investor. After a significant drop in the stock price last week, the new CEO, Stephen Hemsley, made a bold move by purchasing $25 million worth of UNH stock on Friday, May 16, 2025. According to the Form 4 filing with the Securities and Exchange Commission, he acquired 66,700 shares at an average price of $288.57. This substantial investment by the CEO signals a strong vote of confidence in the company's future, especially after what the market has described as a "bloodbath" for the health insurer. I find this development particularly noteworthy as I evaluate my own investment decisions. The questio

$UnitedHealth(UNH)$ is the largest health insurance provider in the United States, holding a dominant position in the industry with a 15% market share. The U.S. healthcare market is vast and characterized by high demand rigidity. The company's business spans multiple areas, including insurance, outpatient services, health data, and health care.Recent Insider Buying ActivityInstitutions, insiders, and significant investors have loaded over 200M+worthofUNH shares within the past few days.Specifically:New CEO purchases $25M on 5/16CFO purchases $5M on 5/16Director purchases $1.5M on 5/15Stock Performance and Market Sentiment $UnitedHealth(UNH)$ has seen a cumulative increase of nearly 30% over the past three t

UnitedHealth Group ( $UnitedHealth(UNH)$ ) has been a punching bag for the market lately, with its stock cratering after a brutal sell-off. But last Friday, new CEO Stephen Hemsley threw a curveball, scooping up 86,700 shares at $288.57 a pop—totaling a cool $25 million—per an SEC Form 4 filing. At $300, UNH is licking its wounds, but is this insider buy a signal to jump in, or a head-fake before more pain? Let’s break it down and figure out if UNH’s got the legs to sprint back to $400—or if it’s just staggering. The Insider Scoop: Hemsley’s $25M Gambit Hemsley isn’t messing around. Dropping $25 million on UNH shares isn’t pocket change—it’s a neon sign flashing “I believe in this.” Insider buying like this often hints at undervaluation, especially

Options Market Statistics: UnitedHealth Stock Rallies After New CEO Buys $25 Million $UnitedHealth(UNH)$   had active options trading, with a total trading volume of 0.72M options for the day, and the put-call ratio is 0.46. The most traded calls are contracts of $320 strike price that expire on May 23 and the total volume reaching 24,789 with the open interest of 4,093. CEO Stephen Hemsley, who returned to the role on Tuesday after Andrew Witty resigned, purchased 86,700 shares at an average price of $288.57, according to a regulatory filing on Friday. CFO John Rex also bought over 17,000 shares, and board member Kristen Gil acquired 3,700 shares. Other directors, including John Noseworthy and Tim Flynn, al

Market OverviewRetail traders went on a record dip buying spree Monday(May 19), reversing a 1% decline in the S&P 500 Index triggered by the US credit downgrade from Moody’s Ratings late last week.Regarding the options market, a total volume of 40,783,578 contracts was traded.Top 10 Option VolumesTop 10: $NVDA(NVDA)$, $TSLA(TSLA)$, $AAPL(AAPL)$, $UNH(UNH)$, $PLTR(PLTR)$, $AMZN(AMZN)$, $MSTR(MSTR)$, $SMCI(SMCI)$,

UnitedHealth dramatic collapse have rattled markets. This collapse has been driven by multiple factors, including a reported Department of Justice (DOJ) criminal investigation into potential Medicare fraud, higher-than-expected medical costs, a historic cyberattack, and public backlash following the murder of UnitedHealthcare CEO Brian Thompson in December 2024. Additionally, the company suspended its 2025 financial guidance and announced a CEO change, with Stephen Hemsley replacing Andrew Witty, further shaking investor confidence. Is It Time to Bottom Fish? "Bottom fishing" involves buying stocks at perceived lows, anticipating a recovery. Here are key considerations for UNH: Valuation: UNH is trading at a low valuation of approximately 10.7 times trailing earnings, which is attractive c

$UnitedHealth(UNH)$  yes but be careful. Fundamentals finance is important plus govt regulations